MALCOLM BRENNER to Hematopoietic Stem Cell Transplantation
This is a "connection" page, showing publications MALCOLM BRENNER has written about Hematopoietic Stem Cell Transplantation.
Connection Strength
4.439
-
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
Score: 0.270
-
Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
Score: 0.248
-
Cellular therapy for cancer: let there be light. Tissue Antigens. 2012 Jan; 79(1):1-3.
Score: 0.214
-
T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol. 2007 Nov; 14(6):616-24.
Score: 0.160
-
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808.
Score: 0.145
-
CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005 Jun; 35(12):1127-32.
Score: 0.135
-
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850.
Score: 0.118
-
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9.
Score: 0.118
-
Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
Score: 0.117
-
Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208.
Score: 0.116
-
Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
Score: 0.114
-
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
Score: 0.102
-
Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695.
Score: 0.091
-
Use of gene marking technologies in oncology. Forum (Genova). 1998 Oct-Dec; 8(4):342-53.
Score: 0.085
-
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
Score: 0.085
-
High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650.
Score: 0.082
-
Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431.
Score: 0.082
-
BMT beats autoimmune disease. Nat Med. 1998 Feb; 4(2):153-5.
Score: 0.081
-
Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541.
Score: 0.080
-
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
Score: 0.079
-
Gene marking and gene therapy for transplantation medicine. J Hematother. 1996 Oct; 5(5):553-5.
Score: 0.074
-
Placental blood transplant: who will benefit? Nat Med. 1996 Sep; 2(9):969-70.
Score: 0.074
-
Transfer of marker genes into hemopoietic progenitor cells. Cytokines Mol Ther. 1996 Sep; 2(3):193-200.
Score: 0.074
-
Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther. 2016 Apr; 24(4):823-31.
Score: 0.070
-
Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5.
Score: 0.070
-
The contribution of marker gene studies to hemopoietic stem cell therapies. Stem Cells. 1995 Sep; 13(5):453-61.
Score: 0.069
-
Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72.
Score: 0.067
-
Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
Score: 0.063
-
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
Score: 0.063
-
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25.
Score: 0.062
-
Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22.
Score: 0.060
-
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
Score: 0.060
-
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
Score: 0.059
-
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
Score: 0.058
-
Gene transfer into human hematopoietic progenitor cells: a review of current clinical protocols. J Hematother. 1993; 2(1):7-17.
Score: 0.057
-
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18.
Score: 0.057
-
Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan; 129(1):176-83.
Score: 0.053
-
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2.
Score: 0.048
-
Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010 Apr; 51(4):664-70.
Score: 0.047
-
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
Score: 0.046
-
Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009 Sep 12; 374(9693):912-20.
Score: 0.045
-
Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009; 675-81.
Score: 0.043
-
Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52.
Score: 0.043
-
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
Score: 0.043
-
Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008 Oct 21; 71(17):1326-34.
Score: 0.043
-
Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep; 40(6):563-6.
Score: 0.039
-
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24.
Score: 0.039
-
Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
Score: 0.038
-
The continuing contribution of gene marking to cell and gene therapy. Mol Ther. 2007 Apr; 15(4):666-76.
Score: 0.038
-
Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81.
Score: 0.031
-
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther. 2003 Aug; 8(2):180-7.
Score: 0.030
-
Cells of the hepatic side population contribute to liver regeneration and can be replenished with bone marrow stem cells. Haematologica. 2003 Apr; 88(4):368-78.
Score: 0.029
-
Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy. 2002; 4(5):433-4.
Score: 0.027
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
Score: 0.023
-
Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease. J Clin Immunol. 2000 Jan; 20(1):1-9.
Score: 0.023
-
Cure of leukemia. Semin Hematol. 1999 Oct; 36(4 Suppl 7):73-83.
Score: 0.023
-
In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
Score: 0.021
-
Gene marking. Gene Ther. 1996 Apr; 3(4):278-9.
Score: 0.018
-
Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther. 2016 04; 24(4):736-45.
Score: 0.018
-
Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7.
Score: 0.015
-
Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61.
Score: 0.013
-
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
Score: 0.011
-
Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004 Feb 01; 103(3):1011-9.
Score: 0.008
-
Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81.
Score: 0.007
-
Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001; 258:221-9.
Score: 0.006
-
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996 May; 2(5):551-5.
Score: 0.005
-
Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 1995 Dec; 2(4):291-7.
Score: 0.004